## **Product** Data Sheet

## MLKL-IN-6

Cat. No.: HY-156119 Molecular Formula:  $C_{20}H_{18}N_4O_5$  Molecular Weight: 394.38

Target: Mixed Lineage Kinase; Necroptosis
Pathway: MAPK/ERK Pathway; Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description

MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects<sup>[1]</sup>.

## **REFERENCES**

[1]. Oh J H, et al. Novel Inhibitor of Mixed-Lineage Kinase Domain-Like Protein: The Antifibrotic Effects of a Necroptosis Antagonist[J]. ACS Pharmacology & Translational Science, 2023....

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA